Genmab — April 2018
-
"Janssen-Cilag international N.V.; Lymphoid malignancies except mature B-cell neoplasms
/ Daratumumab in combination with standard chemotherapy is indicated for the
treatment of paediatric patients from birth to 18 years with T-cell acute lymphoblastic
leukemia and T-cell lymphoblastic lymphoma
Day 120 opinion
Action: For adoption
Oncology" -
-
https://www.fiercebiotech.com/biotech/j-j-says-it-has-15-more-to-splash-r-d-thanks-to-tax-cuts-so-will-we-see-more-pipeline-plays Her lidt om J&J's R&D beholdning for de næste 4 år. De kunne snildt købe Genmab til denne lave pris, de har rigeligt med penge ser det ud til, hvilket ikke kommer bag på nogen eller hur?
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
